Global Pet Inactivated Vaccine Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Pet Inactivated Vaccine Market Research Report 2024
Inactivated vaccines for pets are vaccines made from killed pathogens.
According to Mr Accuracy reports new survey, global Pet Inactivated Vaccine market is projected to reach US$ 711.8 million in 2029, increasing from US$ 490.2 million in 2022, with the CAGR of 5.6% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pet Inactivated Vaccine market research.
According to Our PET Supplies Research Center, the global pet industry reached $ 261 billion in 2022, a year-on-year increase of 11.3%. The United States gains the highest pet penetration rate and becomes the largest pet market. According to the American Pet Products Association (APPA), 66% of American households keep pets, and the total industry sales was about US$136.8 billion, an increase of 10.8% over 2021. According to IVH, the German pet products industry association, the number of pets in Germany reached 33.4 million in 2022, with a total turnover of nearly €6.5 billion. The 2024 China Pet Industry Trend Insight White Paper released by JD shows that the market size of the four major pet physical commodities is increasing year by yearpet supplies account for 45%, pet staple food accounts for nearly 35%, pet snacks account for 12%, and pet medicine and health care account for 377%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pet Inactivated Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Bayer Healthcare
Vetoquinol S.A
Boehringer Ingelheim
Ceva
Eli Lilly
Heska
Merck Animal Health
Merial (Sanofi)
Virbac
Pfizer
Segment by Type
Obtained by Heat Killing
Killed by Chemical Methods such as Formaldehyde
Obtained by Radiation Killing
Dog
Cat
Dird
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Pet Inactivated Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Pet Inactivated Vaccine market is projected to reach US$ 711.8 million in 2029, increasing from US$ 490.2 million in 2022, with the CAGR of 5.6% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Pet Inactivated Vaccine market research.
According to Our PET Supplies Research Center, the global pet industry reached $ 261 billion in 2022, a year-on-year increase of 11.3%. The United States gains the highest pet penetration rate and becomes the largest pet market. According to the American Pet Products Association (APPA), 66% of American households keep pets, and the total industry sales was about US$136.8 billion, an increase of 10.8% over 2021. According to IVH, the German pet products industry association, the number of pets in Germany reached 33.4 million in 2022, with a total turnover of nearly €6.5 billion. The 2024 China Pet Industry Trend Insight White Paper released by JD shows that the market size of the four major pet physical commodities is increasing year by yearpet supplies account for 45%, pet staple food accounts for nearly 35%, pet snacks account for 12%, and pet medicine and health care account for 377%.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Pet Inactivated Vaccine market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Bayer Healthcare
Vetoquinol S.A
Boehringer Ingelheim
Ceva
Eli Lilly
Heska
Merck Animal Health
Merial (Sanofi)
Virbac
Pfizer
Segment by Type
Obtained by Heat Killing
Killed by Chemical Methods such as Formaldehyde
Obtained by Radiation Killing
Segment by Application
Dog
Cat
Dird
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Pet Inactivated Vaccine report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices